ChartRow logo
PeersGILDBMYGSKINCYPFESNY
Share this page

BIIB — Biogen Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in BIIB be worth today? →
BIIB returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$248.41
YTD price return
+41.15%
YTD total return
+41.15%
Market cap
36.7B
Enterprise value
43.5B
Shares outstanding
147.8M
52W low
$151.83
52W high
$258.78
From 52W high
-4.01%
From 52W low
+63.61%
52W range
90%$152–$259
Beta
0.16

Volume

Rel volume
0.52×
30D volume
1.3M
30D $ vol
308.3M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
−$905K

Form 4 transactions by trade date, as filed; latest on file 2026-08-04.

Fundamentals

Sales (ttm)
10.3B
Sales/share
$69.66
EPS (ttm)
$2.34
FCF (ttm)
2.1B
FCF/share
$14.01
Book value/share
$128.01
Net margin
3.37%
ROE
1.84%
ROA
1.08%
Debt / equity
0.39×
Current ratio
1.95

Growth (CAGR, ttm) · 10Y

Sales
+2.30%+1.00%-1.49%-1.03%
Net income
-78.42%-38.05%-25.81%-21.45%
FCF
-10.15%+24.94%-0.67%-4.91%
Shares
+0.76%+0.67%+0.13%-3.79%

Per-share growth (CAGR, ttm) · 10Y

EPS
-78.67%-38.47%-25.51%-18.31%
Sales/share
+1.53%+0.33%-1.62%+2.87%
FCF/share
-10.83%+24.11%-0.80%-1.16%
Book value/share
+3.14%+8.59%+12.51%+8.68%
Price
+58.54%-0.03%-2.27%-1.08%
Total return
+58.54%-0.03%-2.27%-1.08%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
106.0×
P/OI (ttm)
15.6×
Fwd P/E
15.3×
P/S (ttm)
3.6×
P/B (mrq)
1.9×
P/FCF (ttm)
17.7×
EV/EBITDA (fy)
26.6×
EV/Sales (ttm)
4.2×
FCF yield (ttm)
5.64%
Buyback yield (realized, 1y)
-0.76%
Shareholder yield (realized, 1y)
-0.76%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/E
100th
P/OI
91st
P/S
57th
P/B
23rd
P/FCF
68th

Bar = where today’s multiple sits in BIIB’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

1D
+1.84%
5D
-2.05%
1M
+11.45%
3M
+20.42%
YTD
+41.15%
1Y
+58.49%
5Y
-10.86%
1D
+1.84%
5D
-2.05%
1M
+11.45%
3M
+20.42%
YTD
+41.15%
1Y
+58.49%
5Y
-10.86%

Fundamentals#

Revenue

5Y CAGR −6.0%10Y CAGR −0.8%YoY +10.6%
$10.3B TTM$2.8B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −11.2%10Y CAGR +5.1%YoY −37.3%
— FY25— Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −18.7%10Y CAGR −5.4%YoY n/m
$2.34 TTM−$0.14 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR −11.6%10Y CAGR −4.6%YoY −51.0%
$2.1B TTM$600.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $2.2B, capex −$176.4M

Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $640.8M, capex −$40.4M

Shares (diluted)

5Y −8.8%10Y −36.4%YoY +0.5%
148.2M TTM147.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −20.2%10Y CAGR −9.6%YoY n/m
$347.5M TTM−$20.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full BIIB financials →

About Biogen#

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.

Cambridge, MA·7,500 employees·Drug Manufacturers - General·biogen.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding BIIB#

35 of the 193 ETFs ChartRow carries live hold BIIB. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF2.5%
XBISPDR S&P Biotech ETF1.0%
COWZPacer US Cash Cows 100 ETF0.7%
XLVHealth Care Select Sector SPDR Fund0.6%
VOEVanguard Mid-Cap Value ETF0.6%
VHTVanguard Health Care ETF0.4%
IWSiShares Russell Mid-Cap Value ETF0.3%
VOVanguard Mid-Cap ETF0.3%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.43%+1.45%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.15%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.73%-0.40%
NVSNovartis AG+15.44%+0.37%
TMOThermo Fisher Scientific Inc.+5.82%+2.64%
AMGNAmgen Inc.+14.30%-0.03%